<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.02.10.21251350</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Infectious Diseases (except HIV/AIDS)</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>C-reactive protein guided use of procalcitonin in COVID-19</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Houghton</surname><given-names>Rebecca</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Moore</surname><given-names>Nathan</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Williams</surname><given-names>Rebecca</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>El-Bakri</surname><given-names>Fatima</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Peters</surname><given-names>Jonathan</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mori</surname><given-names>Matilde</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Vernet</surname><given-names>Gabrielle</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lynch</surname><given-names>Jessica</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lewis</surname><given-names>Henry</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tavener</surname><given-names>Maryanna</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Durham</surname><given-names>Tom</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bowyer</surname><given-names>Jack</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Saeed</surname><given-names>Kordo</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5772-0322</contrib-id>
<name><surname>Pollara</surname><given-names>Gabriele</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Hampshire Hospitals NHS Foundation Trust</institution>, <country>UK</country></aff>
<aff id="a2"><label>2</label><institution>University Hospital Southampton NHS Foundation Trust</institution>, <country>UK</country></aff>
<aff id="a3"><label>3</label><institution>University of Southampton, School of Medicine</institution>, Southampton, <country>UK</country></aff>
<aff id="a4"><label>4</label><institution>Royal Free London NHS Foundation Trust</institution>, <country>UK</country></aff>
<aff id="a5"><label>5</label><institution>University College London</institution>, <country>UK</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Corresponding author Dr Gabriele Pollara, Division of Infection &#x0026; Immunity, University College London, London, WC1E 6BT, UK. Email: <email>g.pollara@ucl.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.02.10.21251350</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>2</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>10</day>
<month>2</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>2</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="21251350.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>Low procalcitonin (PCT) concentrations (&#x003C;0.5ng/mL) can facilitate exclusion of bacterial co-infection in viral infections, including COVID-19. However, costs associated with PCT measurement preclude universal adoption, indicating a need to identify settings where PCT provides clinical information beyond that offered by other inflammatory markers, such as C-reactive protein (CRP) and white cell count (WCC). In an unselected cohort of 299 COVID-19 patients, we tested the hypothesis that PCT&#x003C;0.5ng/mL was associated with lower levels of CRP and WCC. We demonstrated that CRP values below the geometric mean of the entire patient population had a negative predictive value for PCT&#x003C;0.5ng/mL of 97.6&#x0025; and 100&#x0025; at baseline and 48 hours into admission respectively, and that this relationship was not confounded by intensive care admission or microbiological findings. CRP-guided PCT testing algorithms can reduce costs and support antimicrobial stewardship strategies in COVID-19.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>COVID-19</kwd>
<kwd>procalcitonin</kwd>
<kwd>C-reactive protein</kwd>
<kwd>antimicrobial stewardship</kwd>
</kwd-group>
<counts>
<page-count count="8"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>No external funding was received to undertake the work presented.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>The study was approved by the Research and Development department at Hampshire Hospitals NHS Trust, which in its capacity as IRB, stated that as this was a retrospective review of routine clinical data, formal ethics approval was not required, and that confidential patient information could be used under the COVID-19 COPI notice issued by the UK Department of Health and Social Care.</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Main text</title>
<p>Unnecessary antibiotic prescriptions during the COVID-19 pandemic will increase selection for antibiotic resistance (<xref ref-type="bibr" rid="c1">1</xref>). Optimising antimicrobial stewardship approaches in COVID-19 is a global priority, and a recent study has indicated that procalcitonin (PCT) &#x003C;0.5ng/mL offered a high negative predictive value (&#x003E;95&#x0025;) for the presence of bacterial co-infections (<xref ref-type="bibr" rid="c2">2</xref>). Elevated PCT is associated more frequently with bacterial than viral infections (<xref ref-type="bibr" rid="c3">3</xref>), and thus low PCT can support cessation of antibiotic prescriptions in both COVID-19 and non-COVID-19 settings (<xref ref-type="bibr" rid="c4">4</xref>&#x2013;<xref ref-type="bibr" rid="c8">8</xref>). Unlike the inflammatory markers C-reactive protein (CRP) and white cell count (WCC), PCT is not routinely measured (<xref ref-type="bibr" rid="c9">9</xref>), partly due to the costs associated with its testing (<xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c11">11</xref>). Elevations in PCT, CRP and WCC can be concordant (<xref ref-type="bibr" rid="c12">12</xref>), and therefore a key research question is to identify scenarios in which PCT provides clinical information beyond that offered by other inflammatory markers, in turn informing algorithms that avoid the expense of redundant PCT measurements.</p>
<p>We identified 299 adult patients with compatible clinical syndromes for COVID-19 and SARS-CoV-2 confirmed on molecular testing, admitted to Hampshire Hospitals NHS Trust between 5<sup>th</sup> March and 26<sup>th</sup> April 2020. The measurement of PCT, CRP and WCC at baseline and daily during hospital admission was standard of care. We tested the hypothesis that PCT concentration was closely related to CRP or WCC levels, choosing PCT&#x2265;0.5ng/mL as threshold for the presence of bacterial pulmonary infection (4,7,8,13,14). PCT&#x2265;0.5ng/mL was associated with greater levels of CRP on admission and 48 hours into admission, independent of the need for intensive care unit (ICU) admission during the hospital stay (<xref rid="fig1" ref-type="fig">figs 1A&#x002B;C</xref>). In contrast, PCT&#x2265;0.5ng/mL was associated with only a modestly greater WCC in non-ICU attending patients (<xref rid="fig1" ref-type="fig">fig 1B&#x002B;D</xref>). Next, we used pairwise comparison to test the hypothesis that low levels of CRP/WCC could exclude PCT&#x2265;0.5 ng/ml. We used the geometric mean of CRP or WCC for the entire patient population at each timepoint as cut-offs for low and high levels of these markers. Strikingly, low CRP was strongly associated with PCT &#x003C; 0.5ng/mL (NPV 97.6&#x0025; and 100&#x0025; at baseline and 48 hours into admission respectively) (<xref rid="fig1" ref-type="fig">fig 1C</xref>). A similar relationship was observed for WCC, although with lower NPV (91.0&#x0025; and 84.9&#x0025; respectively) (<xref rid="fig1" ref-type="fig">fig 1D</xref>). Notably, patients with significant microbiological results, as previously defined (<xref ref-type="bibr" rid="c2">2</xref>), were not associated with elevated levels of any inflammatory marker (<xref rid="fig1" ref-type="fig">fig 1C&#x002B;D</xref>) (<xref ref-type="bibr" rid="c9">9</xref>).</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1:</label>
<caption><p>Association between CRP or WCC and the concentration of PCT in COVID-19. Concentration of CRP (A) or enumeration of WCC (B) stratified by PCT concentration &#x003C;0.5 or &#x2265; 0.5ng/mL and by requirement for ICU admission during hospital stay. Assessments were made on admission to hospital (&#x201C;baseline&#x201D;) and 48 hours into hospital admission (&#x201C;48h&#x201D;). All p values derived using 2-tailed Mann-Whitney tests. Relationship between PCT and CRP concentration (C) or WCC (D). Scatter plot horizontal line represent PCT concentration cut-off (&#x2265; 0.5ng/mL) and vertical line represents geometric mean of all patients at each timepoint, independent of PCT concentration. Total number of patients in each quadrant of scatter plot quantified in table below. Red dots and bracketed numbers reflect number of patients with significant microbiological findings. Sensitivity, specificity, PPV and NPV given for CRP (E) or WCC (F) to identify high or low PCT concentrations.</p></caption>
<graphic xlink:href="21251350v1_fig1.tif"/>
</fig>
<p>We demonstrate low CRP concentrations can predict low PCT values in COVID-19, precluding the cost of this test in approximately a third of patients. We acknowledge the retrospective, single-centre nature of the study, and the unspecified interval between symptom onset and hospital admission. However, these limitations are countered by the large, unselected populations, the consistent relationship between variables at both time points, and the independence from ICU admission status. The lack of association between PCT and microbiology results was notable and reminiscent of observations made in COVID-19 for other inflammatory markers (<xref ref-type="bibr" rid="c9">9</xref>). The diagnostic stewardship role for PCT in excluding bacterial co-infection at high CRP levels will need investigating through studies comparing COVID-19 with syndromically-defined bacterial pneumonia (<xref ref-type="bibr" rid="c9">9</xref>,<xref ref-type="bibr" rid="c15">15</xref>).</p>
<p>We declare no conflicts of interest.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>All anonymised data presented in the manuscript is available to others by request of the corresponding author.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Nieuwlaat</surname> <given-names>R</given-names></string-name>, <string-name><surname>Mbuagbaw</surname> <given-names>L</given-names></string-name>, <string-name><surname>Mertz</surname> <given-names>D</given-names></string-name>, <string-name><surname>Burrows</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bowdish</surname> <given-names>DME</given-names></string-name>, <string-name><surname>Moja</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>COVID-19 and Antimicrobial Resistance: Parallel and Interacting Health Emergencies</article-title>. <source>Clin Infect Dis</source>. <year>2020</year> <month>Jun</month> <volume>16</volume>;</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="other"><string-name><surname>May</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chang</surname> <given-names>M</given-names></string-name>, <string-name><surname>Dietz</surname> <given-names>D</given-names></string-name>, <string-name><surname>Shoucri</surname> <given-names>S</given-names></string-name>, <string-name><surname>Laracy</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sobieszczyk</surname> <given-names>ME</given-names></string-name>, <etal>et al.</etal> <article-title>Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2021</year> <month>Jan</month> 25;</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Self</surname> <given-names>WH</given-names></string-name>, <string-name><surname>Balk</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Grijalva</surname> <given-names>CG</given-names></string-name>, <string-name><surname>Williams</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Anderson</surname> <given-names>EJ</given-names></string-name>, <etal>et al.</etal> <article-title>Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia</article-title>. <source>Clin Infect Dis</source>. <year>2017</year> <month>Jul</month> 15;<volume>65</volume>(<issue>2</issue>):<fpage>183</fpage>&#x2013;<lpage>190</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>de Jong</surname> <given-names>E</given-names></string-name>, <string-name><surname>van Oers</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Beishuizen</surname> <given-names>A</given-names></string-name>, <string-name><surname>Vos</surname> <given-names>P</given-names></string-name>, <string-name><surname>Vermeijden</surname> <given-names>WJ</given-names></string-name>, <string-name><surname>Haas</surname> <given-names>LE</given-names></string-name>, <etal>et al.</etal> <article-title>Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial</article-title>. <source>Lancet Infect Dis</source>. <year>2016</year> <month>Jul</month>;<volume>16</volume>(<issue>7</issue>):<fpage>819</fpage>&#x2013;<lpage>827</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="other"><string-name><surname>Williams</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Mair</surname> <given-names>L</given-names></string-name>, <string-name><surname>de Silva</surname> <given-names>TI</given-names></string-name>, <string-name><surname>Green</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>House</surname> <given-names>P</given-names></string-name>, <string-name><surname>Cawthron</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title>Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study</article-title>. <source>J Hosp Infect</source>. <year>2021</year> <month>Jan</month> 20;</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="other"><string-name><surname>Peters</surname> <given-names>C</given-names></string-name>, <string-name><surname>Williams</surname> <given-names>K</given-names></string-name>, <string-name><surname>Un</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Little</surname> <given-names>L</given-names></string-name>, <string-name><surname>Saad</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lendrum</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title>Use of procalcitonin for antibiotic stewardship in patients with COVID-19: A quality improvement project in a district general hospital</article-title>. <source>Clin Med</source>. <year>2020</year> <month>Dec</month> 18;</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Heesom</surname> <given-names>L</given-names></string-name>, <string-name><surname>Rehnberg</surname> <given-names>L</given-names></string-name>, <string-name><surname>Nasim-Mohi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Jackson</surname> <given-names>AIR</given-names></string-name>, <string-name><surname>Celinski</surname> <given-names>M</given-names></string-name>, <string-name><surname>Dushianthan</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit</article-title>. <source>J Glob Antimicrob Resist</source>. <year>2020</year> <month>Jul</month> 25;<volume>22</volume>:<fpage>782</fpage>&#x2013;<lpage>784</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="other"><string-name><surname>Drewett</surname> <given-names>GP</given-names></string-name>, <string-name><surname>Smibert</surname> <given-names>OC</given-names></string-name>, <string-name><surname>Holmes</surname> <given-names>NE</given-names></string-name>, <string-name><surname>Trubiano</surname> <given-names>JA</given-names></string-name>. <article-title>The Use of Procalcitonin as an Antimicrobial Stewardship Tool and a Predictor of Disease Severity in COVID-19</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>2021</year> <month>Jan</month> 25;<fpage>1</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="other"><string-name><surname>Mason</surname> <given-names>CY</given-names></string-name>, <string-name><surname>Kanitkar</surname> <given-names>T</given-names></string-name>, <string-name><surname>Richardson</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Lanzman</surname> <given-names>M</given-names></string-name>, <string-name><surname>Stone</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Mahungu</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>Exclusion of bacterial coinfection in COVID-19 using baseline inflammatory markers and their response to antibiotics</article-title>. <source>J Antimicrob Chemother</source>. <year>2021</year> <month>Jan</month> 19;</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Kip</surname> <given-names>MMA</given-names></string-name>, <string-name><surname>Kusters</surname> <given-names>R</given-names></string-name>, <string-name><surname>IJzerman</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Steuten</surname> <given-names>LMG</given-names></string-name>. <article-title>A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis</article-title>. <source>J Med Econ</source>. <year>2015</year> <month>Jul</month> 20;<volume>18</volume>(<issue>11</issue>):<fpage>944</fpage>&#x2013;<lpage>953</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="other"><string-name><surname>Lubell</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Do</surname> <given-names>NTT</given-names></string-name>, <string-name><surname>Nguyen</surname> <given-names>KV</given-names></string-name>, <string-name><surname>Ta</surname> <given-names>NTD</given-names></string-name>, <string-name><surname>Tran</surname> <given-names>NTH</given-names></string-name>, <string-name><surname>Than</surname> <given-names>HM</given-names></string-name>, <etal>et al.</etal> <article-title>C-reactive protein point of care testing in the management of acute respiratory infections in the Vietnamese primary healthcare setting - a cost benefit analysis</article-title>. <source>Antimicrob Resist Infect Control</source>. <year>2018</year> <month>Oct</month> 4;<issue>7</issue>:<fpage>119</fpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Saeed</surname> <given-names>K</given-names></string-name>, <string-name><surname>Dale</surname> <given-names>AP</given-names></string-name>, <string-name><surname>Leung</surname> <given-names>E</given-names></string-name>, <string-name><surname>Cusack</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mohamed</surname> <given-names>F</given-names></string-name>, <string-name><surname>Lockyer</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal> <article-title>Procalcitonin levels predict infectious complications and response to treatment in patients undergoing cytoreductive surgery for peritoneal malignancy</article-title>. <source>Eur J Surg Oncol</source>. <year>2016</year> <month>Feb</month>;<volume>42</volume>(<issue>2</issue>):<fpage>234</fpage>&#x2013;<lpage>243</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Schuetz</surname> <given-names>P</given-names></string-name>, <string-name><surname>Beishuizen</surname> <given-names>A</given-names></string-name>, <string-name><surname>Broyles</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ferrer</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gavazzi</surname> <given-names>G</given-names></string-name>, <string-name><surname>Gluck</surname> <given-names>EH</given-names></string-name>, <etal>et al.</etal> <article-title>Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use</article-title>. <source>Clin Chem Lab Med</source>. <year>2019</year> <month>Aug</month> 27;<volume>57</volume>(<issue>9</issue>):<fpage>1308</fpage>&#x2013;<lpage>1318</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="other"><string-name><surname>Vaughn</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Gandhi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Petty</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Patel</surname> <given-names>PK</given-names></string-name>, <string-name><surname>Prescott</surname> <given-names>HC</given-names></string-name>, <string-name><surname>Malani</surname> <given-names>AN</given-names></string-name>, <etal>et al.</etal> <article-title>Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study</article-title>. <source>Clin Infect Dis</source>. <year>2020</year> <month>Aug</month> 21;</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Karaba</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Jones</surname> <given-names>G</given-names></string-name>, <string-name><surname>Helsel</surname> <given-names>T</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>LL</given-names></string-name>, <string-name><surname>Avery</surname> <given-names>R</given-names></string-name>, <string-name><surname>Dzintars</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title>Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study</article-title>. <source>Open Forum Infect Dis</source>. <year>2021</year> <month>Jan</month>;<volume>8</volume>(<issue>1</issue>):<fpage>ofaa578</fpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>